Partner Therapeutics secures FDA approval for Bizengri

Out of 22 patients with unresectable or metastatic NRG1+ cholangiocarcinoma, 19 were evaluable for efficacy. Credit: Gorodenkoff / Shutterstock.com.



  • Partner Therapeutics FDA